Plasma Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electroconvulsive therapy

Piccinni, Armando; Debbio, Alessandro Del; Medda, Pierpaolo; Bianchi, Carolina; Roncaglia, Isabella; Veltri, Antonello; Zanello, S.; Massimetti, Enrico; Origlia, Nicola; Domenici, Luciano

doi:10.1016/j.euroneuro.2009.01.002

Cited by 111 publications

(84 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One might consider the selection of serum instead of plasma as the specimen for BDNF as a limitation, however, as mentioned above, data about BDNF levels in serum or plasma of depressive patients are conflicting. Furthermore, it was reported that plasma BDNF has shown high interindividual variability [Piccinni et al 2009]. Lommatzsch and colleagues found that plasma BDNF levels decreased significantly with increasing age, weight or cholesterol, whereas platelet levels (an important source of serum BDNF) did not [Lommatzsch et al 2005].…”

Section: Discussionmentioning

confidence: 99%

Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features

Kotan¹,

Sarandöl²,

Kırhan³

et al. 2012

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Abstract:Objective: Brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF) and leptin have been hypothesized to be involved in the neurobiology of depression. The aim of this study was to investigate BDNF, VEGF and leptin levels in patients with severe melancholic depression. Methods: A total of 40 drug-free patients with major depressive disorder (MDD) with melancholic features and 40 healthy controls were included in the study. Demographic information, psychiatric evaluation and physical examination were documented for both groups. Serum BDNF, VEGF levels were determined by enzyme-linked immunosorbent assay and leptin with radioimmunoassay methods. The Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale were applied to the patients. Results: There were no significant differences in serum BDNF, VEGF and leptin levels between the patient and control groups. There was a negative correlation between BDNF levels and the number of depressive episodes. It was noted that VEGF levels decreased with increasing severity of depression. Conclusions: These findings suggest that BDNF levels might be associated with the recurrence of depression and VEGF levels might be a determinant of the severity of depression.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features

Kotan¹,

Sarandöl²,

Kırhan³

et al. 2012

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Some studies have found no association between improvement in depressive psycho-pathology after ECT, and changes in serum BDNF or other neurotrophic factors (Fernandes et al, 2009;Gronli et al, 2009). However, there have also been reports of positive association between serum BDNF and therapeutic effi cacy of ECT for depression (Piccinni et al, 2009;Viikki et al, 2010a). Activation of glial cells may play a part in mediating the antidepressant effects of ECT (Palmio et al, 2010), and successful ECT may also be associated with elevated serum glial cell-line derived neurotrophic factor (GDNF) levels (Zhang et al, 2009).…”

Section: What Is the Mechanism Of Action?mentioning

confidence: 99%

The Use of ECT and MST in treating depression

Allan

Ebmeier

2011

International Review of Psychiatry

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) has been used clinically since 1938. Its most common use is in the treatment of depression: fi rst line treatment where rapid recovery is a priority, but more frequently as an effective treatment for patients who do not respond to pharmacological and psychological approaches. Whilst it is widely hailed as an effective treatment, concerns about its effect on cognition remain. The development of magnetic seizure therapy (MST) over the past decade has attempted to devise a therapy with comparable effi cacy to ECT, but without the associated cognitive side effects. The rationale for this is that MST uses magnetic fi elds to induce seizures in the cortex, without electrical stimulation of brain structures involved with memory. MST has been used successfully in the treatment of depression, yet there is a dearth of literature in comparison with ECT. We present a systematic review of the literature on ECT (from 2009ECT (from -2011 and MST (from 2001MST (from -2011.

show abstract

“…There is some clinical evidence pointing to a positive correlation between levels of BDNF and anti-depressive treatment response (Shimizu et al 2003, Bocchio-Chiavetto et al 2006, Marano et al 2007, Machado-Vieira et al 2009, Piccinni et al 2009). …”

Section: The Neuroplasticity Hypothesis In Anti-depressive Treatmentmentioning

confidence: 99%

On electroconvulsive therapy in depression : Clinical, cognitive and neurobiological aspects

Nordanskog¹

2015

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) is used worldwide to treat severe mental disorders. The most common mental disorder, and the third leading cause of disease burden in the world is depression. The clinical efficacy of ECT for severe depression is well-established. However, both the pathophysiology of depression and the mechanism of action of ECT remain elusive. The main aims of this thesis are to address the following issues: 1) the use and practice of ECT in Sweden has not been systematically evaluated since 1975, 2) cognitive side-effects (memory disturbances) are a major concern with ECT and 3) the mechanism of action of ECT remain elusive. The neurobiological aspects of ECT focus on two hypotheses. First, the recent years´ preclinical studies that have provided evidence that ECT induces hippocampal cell proliferation, including neurogenesis. Second, that enhanced functional inhibition of neuronal activity is a key feature. Current use and practice of ECT in Sweden (paper I) is based on data from the national quality register for ECT, the mandatory patient register of the National Board of Health and Welfare and a survey. Treated person rate (TPR) in Sweden 2013 was found to be 41 individuals / 100 000, and thus unchanged since the latest systematic investigation in Sweden 1975. In more than 70% of treatment series the indication was a depressive episode. The selection of patients for ECT and treatment technique in Sweden was similar to that in other western countries, but the consent procedure and the involvement of nurses and nursing assistants in the delivery of ECT differ. Data also shows that there is room for improvement in both the specificity of use and availability of ECT. The second study in this thesis is a longitudinal observational trial where 12 (paper II and III) and 14 (paper IV) patients with depression referred for ECT were investigated. Patients underwent a 3 T MRI structural scanning and DSC-MRI perfusion, a neuropsychological test battery and clinical ratings before ECT, within one to two weeks after ECT and after 6 and 12 months. In line with preclinical findings and the plasticity hypothesis of mechanism of action of ECT, the hippocampal volume increased after ECT in patients with depression. However, this increase was transient and returned to baseline levels within 6 months. No correlation was found between volumetric changes and clinical effect or cognitive outcome. Instead our results suggested an association to the number of treatments, without relation to the side of stimulation. A right-sided decrease in frontal blood flow distinguished remission from non-remission after ECT. There were significant impairments in verbal episodic memory and verbal fluency within one week after ending the ECT course, but these impairments were transient and no persistent cognitive impairments were seen during the follow-up. In summary, this thesis present the first update on the use and practice of ECT in Sweden in the last 40 years as well as a pioneering MRI-study on the hippocampal volume increase...

show abstract

Plasma Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electroconvulsive therapy

Cited by 111 publications

References 54 publications

Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features

Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features

The Use of ECT and MST in treating depression

On electroconvulsive therapy in depression : Clinical, cognitive and neurobiological aspects

Contact Info

Product

Resources

About